190 related articles for article (PubMed ID: 20646345)
21. Topical calcipotriene 0.005% and betamethasone dipropionate 0.064% maintains efficacy of etanercept after step-down dose in patients with moderate-to-severe plaque psoriasis: results of an open label trial.
Kircik LH
J Drugs Dermatol; 2011 Aug; 10(8):878-82. PubMed ID: 21818509
[TBL] [Abstract][Full Text] [Related]
22. Treatment of erythrodermic psoriasis with etanercept.
Esposito M; Mazzotta A; de Felice C; Papoutsaki M; Chimenti S
Br J Dermatol; 2006 Jul; 155(1):156-9. PubMed ID: 16792768
[TBL] [Abstract][Full Text] [Related]
23. Once-weekly administration of high-dosage Etanercept in patients with plaque psoriasis: results of a pilot experience (power study).
Cassano N; Loconsole F; Galluccio A; Miracapillo A; Pezza M; Vena GA
Int J Immunopathol Pharmacol; 2006; 19(1):225-9. PubMed ID: 16569361
[TBL] [Abstract][Full Text] [Related]
24. A multicenter, randomized, open-label pilot trial assessing the efficacy and safety of etanercept 50 mg twice weekly followed by etanercept 25 mg twice weekly, the combination of etanercept 25 mg twice weekly and acitretin, and acitretin alone in patients with moderate to severe psoriasis.
Lee JH; Youn JI; Kim TY; Choi JH; Park CJ; Choe YB; Song HJ; Kim NI; Kim KJ; Lee JH; Yoo HJ
BMC Dermatol; 2016 Jul; 16(1):11. PubMed ID: 27455955
[TBL] [Abstract][Full Text] [Related]
25. Patient-reported outcomes and health-care resource utilization in patients with psoriasis treated with etanercept: continuous versus interrupted treatment.
Gelfand JM; Kimball AB; Mostow EN; Chiou CF; Patel V; Xia HA; Freundlich B; Stevens SR
Value Health; 2008; 11(3):400-7. PubMed ID: 18489665
[TBL] [Abstract][Full Text] [Related]
26. Utilization of narrow-band ultraviolet light B therapy and etanercept for the treatment of psoriasis (UNITE): efficacy, safety, and patient-reported outcomes.
Kircik L; Bagel J; Korman N; Menter A; Elmets CA; Koo J; Yang YC; Chiou CF; Dann F; Stevens SR;
J Drugs Dermatol; 2008 Mar; 7(3):245-53. PubMed ID: 18380206
[TBL] [Abstract][Full Text] [Related]
27. The efficacy and safety of etanercept when used with as-needed adjunctive topical therapy in a randomised, double-blind study in subjects with moderate-to-severe psoriasis (the PRISTINE trial).
Strohal R; Puig L; Chouela E; Tsai TF; Melin J; Freundlich B; Molta CT; Fuiman J; Pedersen R; Robertson D
J Dermatolog Treat; 2013 Jun; 24(3):169-78. PubMed ID: 22251226
[TBL] [Abstract][Full Text] [Related]
28. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction.
Papp KA; Tyring S; Lahfa M; Prinz J; Griffiths CE; Nakanishi AM; Zitnik R; van de Kerkhof PC; Melvin L;
Br J Dermatol; 2005 Jun; 152(6):1304-12. PubMed ID: 15948997
[TBL] [Abstract][Full Text] [Related]
29. Influence and variation of the body mass index in patients treated with etanercept for plaque-type psoriasis.
Esposito M; Mazzotta A; Saraceno R; Schipani C; Chimenti S
Int J Immunopathol Pharmacol; 2009; 22(1):219-25. PubMed ID: 19309569
[TBL] [Abstract][Full Text] [Related]
30. Adalimumab for psoriasis patients who are non-responders to etanercept: open-label prospective evaluation.
Martyn-Simmons CL; Green L; Ash G; Groves RW; Smith CH; Barker JN
J Eur Acad Dermatol Venereol; 2009 Dec; 23(12):1394-7. PubMed ID: 19573024
[TBL] [Abstract][Full Text] [Related]
31. Treatment of psoriasis with different dosage regimens of etanercept: preliminary results from the Tαranta Plastic Study Group.
Cassano N; Loconsole F; Miracapillo A; Travaglini M; Digiuseppe MD; Congedo M; Galluccio A; Buquicchio R; Mastrandrea V; Filieri M; Raho G; Pezza M; Vena GA
Int J Immunopathol Pharmacol; 2010; 23(3):797-802. PubMed ID: 20943050
[TBL] [Abstract][Full Text] [Related]
32. A Randomized, blinded assessor study to Evaluate the efFIcacy and safety of etanercept 50 mg once weekly plus as Needed topical agent vs. Etanercept 50 mg twice weekly in patients with moderate to severe plaque psoriasis (REFINE).
Papp KA; Barber K; Bissonnette R; Bourcier M; Lynde CW; Poulin Y; Shelton J; Toole J; Vieira A; Poulin-Costello M
J Eur Acad Dermatol Venereol; 2015 Feb; 29(2):361-366. PubMed ID: 24980988
[TBL] [Abstract][Full Text] [Related]
33. Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population.
Papp KA; Poulin Y; Bissonnette R; Bourcier M; Toth D; Rosoph L; Poulin-Costello M; Setterfield M; Syrotuik J
J Am Acad Dermatol; 2012 Feb; 66(2):e33-45. PubMed ID: 20850895
[TBL] [Abstract][Full Text] [Related]
34. Self-reported health outcomes in patients with psoriasis and psoriatic arthritis randomized to two etanercept regimens.
Gniadecki R; Robertson D; Molta CT; Freundlich B; Pedersen R; Li W; Boggs R; Zbrozek AS
J Eur Acad Dermatol Venereol; 2012 Nov; 26(11):1436-43. PubMed ID: 22035157
[TBL] [Abstract][Full Text] [Related]
35. Two years of experience with etanercept in recalcitrant psoriasis.
Ahmad K; Rogers S
Br J Dermatol; 2007 May; 156(5):1010-4. PubMed ID: 17408393
[TBL] [Abstract][Full Text] [Related]
36. [Clinical experience with etanercept in the treatment of psoriasis].
Martín B; Sánchez-Carazo JL; Pérez-Ferriols A; Laguna C; Oliver V; Alegre V
Actas Dermosifiliogr; 2008 Sep; 99(7):540-5. PubMed ID: 18682167
[TBL] [Abstract][Full Text] [Related]
37. Treating psoriasis with etanercept in italian clinical practice: prescribing practices and duration of remission following discontinuation.
Arcese A; Aste N; Bettacchi A; Camplone G; Cantoresi F; Caproni M; D'Amico D; Fabbri P; Filosa G; Galluccio A; Hansel K; Lisi P; Micali G; Musumeci ML; Nicolini M; Parodi A; Patania M; Pezza M; Potenza C; Richetta A; Simonacci M; Trevisan P; Valenti G; Calvieri S
Clin Drug Investig; 2010; 30(8):507-16. PubMed ID: 20586516
[TBL] [Abstract][Full Text] [Related]
38. Cost effectiveness of biologic therapies for plaque psoriasis.
Ahn CS; Gustafson CJ; Sandoval LF; Davis SA; Feldman SR
Am J Clin Dermatol; 2013 Aug; 14(4):315-26. PubMed ID: 23696234
[TBL] [Abstract][Full Text] [Related]
39. Our experience with etanercept in the treatment of psoriasis.
Kokelj F; Miertusova Tothova S; Patamia M; Trevisan G
Acta Dermatovenerol Croat; 2006; 14(4):241-5. PubMed ID: 17311738
[TBL] [Abstract][Full Text] [Related]
40. Comparison of clinical and pharmacokinetic profiles of etanercept 25 mg twice weekly and 50 mg once weekly in patients with psoriasis.
Elewski B; Leonardi C; Gottlieb AB; Strober BE; Simiens MA; Dunn M; Jahreis A
Br J Dermatol; 2007 Jan; 156(1):138-42. PubMed ID: 17199580
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
